Search research articles
Contact Us
Filters
Showing results (361-370 of 406) with videos related to
Page
of 41
Sort By:
Journal of Drugs in Dermatology : JDD
|
May 12, 2016
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials
M Alan Menter, Kim A Papp, Jennifer Cather, et al.
The Journal of Allergy and Clinical Immunology
|
October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies
Emma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology
|
August 8, 2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
Kim A Papp, Andrew Blauvelt, Lluís Puig, et al.
Lancet (London, England)
|
August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.
Journal of Cutaneous Medicine and Surgery
|
November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document
Melinda J Gooderham, Chih-Ho Hong, Lorne Albrecht, et al.
Journal of Cutaneous Medicine and Surgery
|
November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Chih-Ho Hong, Melinda J Gooderham, Lorne Albrecht, et al.
The New England Journal of Medicine
|
April 20, 2017
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, et al.
The British Journal of Dermatology
|
July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 15, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
K Reich, J I Silverberg, K A Papp, et al.
American Journal of Clinical Dermatology
|
November 12, 2022
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
Linda Stein Gold, Javier Alonso-Llamazares, Zoe D Draelos, et al.
Page
of 41
Search research articles
Search
Showing results (361-370 of 406) with videos related to
Sort By:
Page
of 41
Journal of Drugs in Dermatology : JDD
|
May 12, 2016
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials
M Alan Menter, Kim A Papp, Jennifer Cather, et al.
The Journal of Allergy and Clinical Immunology
|
October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies
Emma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology
|
August 8, 2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
Kim A Papp, Andrew Blauvelt, Lluís Puig, et al.
Lancet (London, England)
|
August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.
Journal of Cutaneous Medicine and Surgery
|
November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document
Melinda J Gooderham, Chih-Ho Hong, Lorne Albrecht, et al.
Journal of Cutaneous Medicine and Surgery
|
November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Chih-Ho Hong, Melinda J Gooderham, Lorne Albrecht, et al.
The New England Journal of Medicine
|
April 20, 2017
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, et al.
The British Journal of Dermatology
|
July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 15, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
K Reich, J I Silverberg, K A Papp, et al.
American Journal of Clinical Dermatology
|
November 12, 2022
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
Linda Stein Gold, Javier Alonso-Llamazares, Zoe D Draelos, et al.
Page
of 41